Dimethylfumarate Inhibits Tumor-Necrosis-Factor-Induced CD62E Expression in an NF-κB-Dependent Manner  by de Martin, Rainer et al.
Dimethylfumarate Inhibits Tumor-Necrosis-Factor-Induced
CD62E Expression in an NF-kB-Dependent Manner
Robert Loewe,1 Manuela Pillinger,1 Rainer de Martin,* Ulrich Mrowietz,² Marion GroÈger,
Wolfgang Holnthoner, Klaus Wolff, Wolfgang Wiegrebe,³ David Jirovsky,³ and Peter Petzelbauer
Department of Dermatology, Division of General Dermatology, and *Institute for Vascular Biology and Thrombosis Research, University of Vienna
Medical School, Vienna, Austria; ²Department of Dermatology, University of Kiel, Kiel, Germany; ³Institute of Pharmacy, University of Regensburg,
Regensburg, Germany
Fumaric acid esters are thought to improve psoriasis
by altering leukocyte, keratinocyte, and/or endothe-
lial functions. To determine speci®city, kinetics, and
molecular mechanisms of different fumaric acid
esters in their ability to inhibit endothelial cell acti-
vation, we analyzed CD62E and CD54 expression in
endothelial cells in vivo and in vitro. In lesional skin of
psoriatic patients, oral fumaric acid ester treatment
resulted in a marked reduction of CD62E but not
CD54 expression on dermal microvessels. Using
human umbilical vein endothelial cells, dimethylfu-
marate almost completely inhibited tumor-necrosis-
factor-induced CD62E, but not CD54 expression at
concentrations %70 mM, mimicking the situation
in vivo. A 60 min dimethylfumarate preincubation
was suf®cient to block tumor-necrosis-factor-
induced CD62E expression for up to 24 h. In
contrast, equimolar concentrations of methylhydro-
genfumarate, the hydrolysis product of dimethylfu-
marate, did not suppress tumor-necrosis-factor-
induced CD62E expression. Likewise, all fumaric
acid esters other than dimethylfumarate were inef-
fective. Using CD62E, NF-kB, or AP-1-responsive
promoter constructs, dimethylfumarate inhibited
tumor-necrosis-factor-induced activation of the
CD62E and the NF-kB but not the AP-1 promoter
construct. In summary, at a dose range %70 mM,
dimethylfumarate appeared to be a speci®c inhibitor
of CD62E expression in an NF-kB-dependent man-
ner. Key words: CD54/endothelial cells/fumaric acid
esters/methylhydrogenfumarate/psoriasis. J Invest Dermatol
117:1363±1368, 2001
F
umaric acid esters (FAE) have been used empirically in
the treatment of psoriasis for many years (reviewed by
Mrowietz et al, 1999). In the ®rst controlled study, a
therapeutic potency was shown for dimethylfumarate
(DMF) only and not for salts of ethylhydrogenfumarates
(EHF) (Nieboer et al, 1989). Kolbach et al used a combination of
DMF plus EHF salts and found this mixture superior to DMF alone
(Kolbach and Nieboer, 1992). As all subsequent open and
controlled clinical studies used this mixture of FAE (Altmeyer
et al, 1994; Mrowietz et al, 1998), questions regarding the most
active ingredient(s) of the FAE mixture and the mode of action are
still under debate. The situation is further complicated by the fact
that, due to its chemical structure, DMF hydrolyzes into
methylhydrogenfumarate (MHF) and methanol, but MHF has yet
not been tested in a monotherapy regimen.
In vitro studies have only partially resolved the question of
individual ef®cacies of different FAE. For example, in lymphocytes,
MHF modulated cytokine expression towards a Th2 cytokine
pro®le (de Jong et al, 1996; Asadullah et al, 1997). Subsequent work
employing a different setup con®rmed and extended these data by
showing that also DMF switched T cell responses towards a Th2
cytokine pro®le (Ockenfels et al, 1998). Likewise, in keratinocytes,
both MHF and DMF inhibited keratinocyte proliferation (Thio
et al, 1994). Both MHF and DMF inhibited monocyte differen-
tiation into dendritic cells (Zhu and Mrowietz, 2001). In vascular
endothelial cells, DMF but not EHF suppressed tumor necrosis
factor (TNF) induced endothelial adhesion molecule expression,
but MHF has not yet been tested (Vandermeeren et al, 1997).
We therefore analyzed the effect of different FAE on CD62E
and CD54 expression in vascular endothelial cells in vivo and in vitro.
CD62E and CD54 are inducible endothelial adhesion molecules.
They play a very important role in mechanisms governing
tethering, rolling, and tight adhesion of leukocytes on endothelial
cell surfaces. This cascade of events is required to initiate and
perpetuate tissue in¯ammation (Bevilacqua et al, 1989; Lawrence
et al, 1995). Here, we show that DMF, but not MHF, at
concentrations %70 mM, is a speci®c inhibitor of CD62E expres-
sion in an NF-kB-dependent manner.
MATERIALS AND METHODS
Cell culture and reagents Human umbilical vein endothelial cells
(HUVEC) were isolated from umbilical cords and cultured as described
previously (Petzelbauer et al, 1993). HUVEC were grown in Iscove's
modi®ed Dulbecco's medium (IMDM; Life Technologies, Gaithersburg,
MD) containing 20% heat-inactivated fetal bovine serum (Life
Manuscript received March 6, 2001; revised July 26, 2001; accepted for
publication August 9, 2001.
Reprint requests to: Dr. Peter Petzelbauer, Department of Dermatology,
Division of General Dermatology, University of Vienna Medical School,
Waehringer Guertel 18±20, A-1090 Vienna, Austria. Email: peter.petzel-
bauer@akh-wien.ac.at
Abbreviations: CaMF, calcium bis(monomethylfumarate); DMF, di-
methylfumarate; EHF, ethylhydrogenfumarate; FA, fumaric acid; FAE,
fumaric acid esters; HUVEC, human umbilical vein endothelial cells;
MHF, methylhydrogenfumarate.
1These authors contributed equally to this work.
0022-202X/01/$15.00 ´ Copyright # 2001 by The Society for Investigative Dermatology, Inc.
1363
Technologies), 2 mM per l glutamine (Life Technologies), 50 IU per ml
penicillin±streptomycin (Life Technologies), and endothelial cell growth
supplement with heparin (Promocell, Heidelberg, Germany). Cells were
used between passages 2 and 6. TNF-a was purchased from Strathmann
Biotech (Hamburg, Germany) and used at a concentration of 10 ng per
ml. All FAE were from Fumapharm (Muri, Switzerland). DMF was
dissolved in methanol as a 70 mM stock solution. Fumaric acid (FA),
calcium bis(monomethylfumarate) (CaMF), MHF, and EHF were
prepared as a 70 mM stock solution in IMDM and stored for up to 3 d.
Fumaderm (Fumamedica, Herne, Germany) is the only FAE registered
for oral treatment of psoriasis. One tablet consists of DMF (120 mg) and
a mixture of Ca2+, Mg2+, and Zn2+ salts of EHF (95 mg). Maximal daily
dose is six tablets.
Immunohistochemistry After informed consent, 5 mm punch
biopsies from lesional and nonlesional skin of three patients with severe
psoriasis before and during systemic therapy with FAE (Fumaderm) were
obtained from the Department of Dermatology of the University of Kiel,
Germany. The biopsies were snap frozen in liquid nitrogen and shipped
on dry ice. Specimens were cut on a Leica cryostat (Vienna, Austria), air
dried, and ®xed with acetone for 10 min at 4°C. Then, a three-step
immunohistochemistry technique was performed using the ABC
Vectastain kit (Vector Laboratories, Burlingame, CA) as described
previously (Petzelbauer et al, 1993). First-step reagents were CD54
(clone BBIG-I1) and CD62E (clone BBIG-E4) (both R&D Systems,
Minneapolis, MN). Bound peroxidase was visualized by 3-amino-9-
ethylcarbazole (Sigma-Aldrich, Deisenhofen, Germany). Sections were
counterstained with Mayers Hemalaun and examined with an Olympus
microscope (Olympus Optical, Hamburg, Germany).
Fluorescence-activated cell sorter (FACS) analysis Con¯uent
HUVEC were stimulated with TNF for 4 h in the presence or absence
of the indicated FAE. Cells were suspended in trypsin/ethylenediamine
tetraacetic acid (Life Technologies), washed in phosphate-buffered saline
(PBS), and incubated with CD54, CD62E, or mouse IgG1 k isotype
control (MOPC 31c, Sigma-Aldrich) in PBS (each 1 mg per ml) for
30 min on ice. After additional washings and incubation with the
¯uorescein isothiocyanate conjugated second-step antimouse IgG
antibody (Sigma-Aldrich, 1 mg per ml) for 30 min on ice, surface-bound
¯uorescence was analyzed by FACScan (Becton Dickinson, San Jose,
CA). Total ¯uorescence values were calculated as described previously
(Petzelbauer et al, 1993); brie¯y the absolute number of positive cells was
multiplied by the mean channel ¯uorescence corrected for the individual
background. Data were pooled from three or ®ve experiments and the
mean 6 SD was calculated.
RNA isolation and northern hybridization Total RNA was isolated
using the RNEasy Kit from Qiagen (Hilden, Germany). A total of 10 mg
RNA was mixed with RNA loading buffer (Sigma-Aldrich) and
denatured for 10 min at 65°C prior to separation on a 0.8% agarose gel.
RNA was transferred on Nylon membranes and stained with methylene
blue. Probes for CD62E and CD54 (a cocktail of six oligonucleotide
antisense probes, R&D Systems) were end-labeled with 32P by using T4
polynucleotide kinase. Blots were hybridized with the labeled probes in
ExpressHyb buffer (Amersham, Buckinghamshire, U.K.) for 60 min at
42°C, and then washed with 2 3 SSC (0.3 M NaCl, 30 mM sodium
citrate) plus 0.1% sodium dodecyl sulfate (SDS) ®rst, then in 0.5% SSC
plus 0.1% SDS two times, and a last wash with 0.25 3 SSC plus 0.1%
SDS. The blots were then exposed to Kodak ®lms (Eastman Kodak,
Rochester, NY) for 1 or 2 d. Northern signals were determined by
densitometry (Kodak electrophoresis documentation and analysis system
120) and normalized to their 28S RNA bands.
Reporter assays A triplicate of the consensus AP-1 site (48 bp, 3¢-
TGTGATGACTCAGGTT) or a triplicate of the consensus NF-kB site
(60 bp, 3¢-AATCGTGGAATTTCCTCTGA) ¯anked by SpeI sites were
inserted into the SpeI site of the pTK-UBT-luc vector, respectively (de
Martin et al, 1993). A 1.3 kb construct of the CD62E promoter spanning
from bp ±1285 to bp +482 was inserted into the NdeI site of the
pMAM neo-luc vector (Clontech) as described previously (Cooper et al,
1996). Cells were transfected using the standard Ca2+ phosphate
precipitation method as described elsewhere (Gille et al, 1996). Brie¯y,
HUVEC between passages 3 and 5 were seeded in gelatine-coated six-
well plates (Falcon) and grown to 70%±80% con¯uence. For transfection,
2.5 mg of the respective promoter construct was added per well. To
control for transfection ef®ciency, cotransfection with 500 ng of a pSV-
b-galactosidase control vector (Promega, Madison, WI) was performed in
each experiment. Two days after transfection, cells were stimulated for
2 h with 10 ng per ml TNF with or without 40 mM DMF. Cells were
then trypsinized, pelleted, rinsed, and resuspended in 200 ml reporter lysis
buffer (Promega) for 15 min according to the manufacturer's
instructions. Luciferase activity was measured with a Berthold
AutoLumat LB9507 luminometer using the luciferase assay system
(Promega). b-Galactosidase activity was determined by a b-galactosidase
enzyme assay system (Promega). Luciferase activities obtained with the
respective promoter constructs were normalized according to their
Figure 1. Fumaric acid derivatives inhibit
CD62E expression in vivo. Immunohisto-
chemistry of psoriatic skin lesions. Five millimeter
punch biopsies were obtained before and after 7,
21, and 35 d of therapy with FAE (Fumaderm).
The daily DMF dosages were 60 mg DMF and
150 mg EHF (Ca2+, Mg2+, and Zn2+ salts)
between days 1±7, 120 mg DMF and 95 mg EHF
salts between days 8±21, and 360 mg DMF and
285 mg EHF salts between days 22 and 35. Serial
sections of the specimens were stained with
CD62E (A±D) and CD54 (E±H).
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b-galactosidase activity. The variation of b-galactosidase activity within
individual experiments was < 10%.
RESULTS
FAE suppress CD62E expression in vivo Skin biopsies of
psoriatic lesions and normal skin before and at weeks 1, 3, and 5
during oral treatment with FAE (Fumaderm) were analyzed for
CD62E and CD54 expression. To allow a semiquantitative
evaluation of the staining intensity with the respective antibodies,
we performed serial dilutions of monoclonal antibodies. For
CD62E, at a concentration of 0.3 mg per ml, minimal reactivity
was seen in untreated lesional skin and CD62E staining was
undetectable at days 7 through 35 after the initiation of treatment.
At 3 mg per ml, strong reactivity was seen at days zero and 7, and
staining was undetectable at days 22 and 35. Staining at an antibody
concentration of 1 mg per ml is shown in Fig 1, showing strong
CD62E reactivity at day zero, weak reactivity at day 7, and no
reactivity thereafter. For CD54, at a concentration of 0.3 mg per
ml, all specimens showed an equally weak staining pattern; at 3 mg
per ml all specimens uniformly showed strong staining. Also the
CD54 expression on keratinocytes and dermal in®ltrating cells
persisted. Histologically, lesions still showed a psoriatic phenotype.
Clinical improvement was seen at day 21. Centers have cleared at
day 35 with active margins still present.
DMF suppresses CD62E expression in cell culture The
effects of different FAE and of FA on TNF-induced CD62E
expression in HUVEC are shown in Fig 2(A). DMF completely
blocked the TNF-induced CD62E expression at concentrations
%70 mM compared with the FA control and with other FAE
tested. A less than 10% inhibition of CD62E expression by FAE
other than DMF was seen at concentrations of 700 mM. Methanol
did not inhibit TNF-induced expression of CD62E at any
concentration tested. A summary of three independent
experiments comparing DMF and MHF effects on CD62E
expression is shown in Fig 2(B). Figure 2(C) compares the
inhibitory effect of DMF on CD62E with that on CD54
expression. At 25 and 40 mM, DMF inhibited CD62E but not
CD54 expression. A minimal reduction of CD54 expression was
seen at 140 mM DMF. In order to see a signi®cant inhibition of
CD54 expression by DMF, concentrations had to be raised to
700 mM (data not shown).
A 60 min preincubation period with DMF is suf®cient to
prevent subsequent TNF-induced CD62E expression In the
next set of experiments, we tested onset and duration of DMF
effects. HUVEC were pretreated with DMF for 1, 10, or 60 min.
DMF was then removed, and cells were rested for various periods
of time up to 24 h and then stimulated with TNF. Following a 1 or
10 min DMF preincubation, subsequent TNF-induced CD62E
expression was not inhibited. In contrast, after a 60 min
Figure 2. Effects of FAE on CD62E and
CD54 expression in vitro. (A) Flow cytometric
analysis of CD62E expression in HUVEC. Cells
were TNF-treated without or with the indicated
concentrations of FA, FAE, or methanol alone.
Bold lines represent CD62E expression, dotted lines
isotype control staining. One representative out of
three experiments is shown. (B) Summary of three
independent experiments. Total ¯uorescence
values are calculated as described in Materials and
Methods, mean 6 SD. Hatched bar, TNF-
stimulated cells; closed bars, DMF plus TNF; open
bars, MHF plus TNF. (C) Flow cytometric
analysis comparing CD62E (3 h TNF) and CD54
(18 h TNF) expression at different concentrations
of DMF. One representative out of four
experiments is shown.
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preincubation with DMF subsequent TNF-induced CD62E
expression was inhibited for up to 24 h and returned to normal
thereafter. Results of a 4 h resting period are shown in Fig 3.
DMF inhibits TNF-induced CD62E mRNA
expression CD62E and CD54 mRNA expression was
analyzed by northern blot analysis (Fig 4). HUVEC were
preincubated with DMF or FA and then stimulated with TNF
for various times. Due to the different inducibility of the two
proteins tested, different time courses were chosen. CD62E
mRNA is inducible by TNF within the ®rst 3 h. Therefore,
mRNA from HUVEC stimulated with TNF for 1 and 3 h and
pretreated with DMF or FA was compared. After 1 h of stimulation
with TNF, CD62E mRNA was detectable in HUVEC
preincubated with FA. After 3 h of stimulation, the detectable
CD62E mRNA signal increased nearly 3-fold. After preincubation
with DMF, after 1 or 3 h of TNF stimulation, CD62E mRNA was
nearly undetectable, resulting in a dramatically reduced CD62E
protein expression detected by FACS analysis. On the other hand,
CD54 mRNA is inducible over a more prolonged period of time,
re¯ecting the transcriptional control exerted by different
transcription factors. Therefore, HUVEC were stimulated for up
to 18 h with TNF. After preincubation with FA, CD54 mRNA
was strongly detectable after 3 and 12 h of stimulation; after 18 h
the signal intensity slowly decreased. HUVEC preincubated with
DMF showed a reduced amount of mRNA after 3 h of incubation,
but after 12 or 18 h the detectable amount of mRNA compared
with the FA preincubated cells was equal or even slightly increased.
DMF inhibits NF-kB but not AP-1-dependent
transcription HUVEC transfected with the CD62E promoter
or constructs containing NF-kB or AP-1 binding sites were treated
with TNF with or without 40 mM DMF (Fig 5). Cells transfected
with the CD62E promoter showed a mean 8-fold increase in
luciferase activity following a 2 h TNF stimulation, which was
inhibited by DMF (p < 0.05). The level of inhibition by 40 mM
DMF seen in the CD62E promoter construct roughly
corresponded to the DMF-induced inhibition of CD62E protein
expression at the same concentration. Similarly, using an NF-kB-
responsive construct, the TNF-induced increase in luciferase
activity was signi®cantly inhibited by DMF. In contrast, using an
AP-1-responsive construct, DMF had no effect on TNF-induced
luciferase activity.
DISCUSSION
Recruitment of white blood cells from the circulation into tissues
strongly depends on the expression of endothelial adhesion
molecules. Many of these molecules are inducible by TNF.
Indeed, several in¯ammatory diseases bene®t from an inhibition of
TNF-mediated cell activation (Neurath et al, 1996; Paleolog et al,
1996). Here, we demonstrate that DMF inhibits TNF-induced
endothelial cell activation, as evidenced by reduced endothelial
CD62E expression in psoriatic skin in vivo and reduced CD62E
mRNA and protein expression in vitro. Likewise, DMF inhibited
transcription of a CD62E promoter construct and of an NF-kB
reporter construct to a similar extent, but not of an AP-1 construct.
This is in line with the fact that CD62E promoter activation mainly
depends on NF-kB (Schindler and Baichwal, 1994; Read et al,
1997) and allows the conclusion that DMF inhibited CD62E
expression at the transcriptional level in an NF-kB-dependent way.
The speci®city of DMF to inhibit CD62E expression is dose
dependent and seen at concentrations %70 mM. At these concen-
trations DMF did not block CD54 expression. In contrast to
CD62E expression, which is mainly under the control of NF-kB,
regulation of CD54 expression is more complex (Roebuck and
Finnegan, 1999). The CD54 promoter is activated by three major
pathways, through NF-kB, AP-1, and through JAK/STAT
pathways, which partly interact and partly overlap. TNF activates
CD54 gene expression through NF-kB and AP-1, whereas JAK/
STAT activation occurs through interferons. In cell culture, CD54
mRNA expression was slightly reduced 3 h following TNF
stimulation re¯ecting the NF-kB-dependent early phase of CD54
induction. At later time points, no inhibition of CD54 mRNA
could be detected. In contrast, after 12 and 18 h the amount of
detectable CD54 mRNA was slightly higher in the DMF-
pretreated cells as determined by relative band densities. It is
known that the AP-1-dependent transcription of CD54 starts at a
later time point; therefore the mRNA levels at 12 and 18 h of
incubation re¯ect the not inhibited AP-1-dependent gene tran-
scription. CD62E mRNA expression was nearly totally inhibited
during the whole time course. Corresponding to the effects of
DMF on the mRNA expression of CD54, CD54 protein
expression was not inhibited by %70 mM DMF. It is thus likely
Figure 3. A 60 min preincubation with DMF inhibits subsequent
TNF-induced CD62E expression. Summary of ®ve independent
experiments. Total ¯uorescence values are calculated as total ¯uorescence
values 6 SD as described in Materials and Methods. After preincubation
with DMF for the indicated times, cells were washed and cultured in
medium alone for another 4 h. Cells were then stimulated with TNF for
4 h. Hatched bar, CD62E expression of TNF-stimulated cells; closed bars,
pretreatment of 40 mM DMF plus TNF; open bars, pretreated cells with
140 mM DMF plus TNF.
Figure 4. DMF inhibits CD62E mRNA expression. RNA was
isolated from 106 HUVEC after preincubation with 40 mM DMF or FA
and stimulation with TNF for the indicated times. After incubation, total
RNA was prepared and northern blotting with probes against CD62E
and CD54 was performed. Control of equal RNA content was
performed by agarose gel electrophoresis of aliquots of the prepared
RNA samples, visualized with ethidium bromide. Relative band densities
calculated by the Kodak electrophoresis documentation and analysis
system 120 are shown.
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that the reduced NF-kB-dependent transcription is balanced by
AP-1. Indeed, transcription of an AP-1 reporter construct was not
affected by DMF. Moreover, this ®nding correlated with our
observation in vivo, where CD54 expression remained unchanged
throughout a treatment period of 5 wk.
DMF readily hydrolyzes into MHF and methanol. Therefore,
MHF and not DMF was believed to mediate the biologic response
(Nibbering et al, 1993). Our experiments using endothelium,
however, demonstrated that MHF, at equimolar concentrations to
DMF, did not inhibit CD62E expression. Thus, in the context of
endothelial cells, MHF is unlikely to be the active metabolite of
DMF. We wish to point out that effects of FAE on endothelial cells
differ from those on lymphocytes and keratinocytes, where both
DMF and MHF appear equally effective (Thio et al, 1994; de Jong
et al, 1996).
The mechanism by which DMF transmits signals to endothelial
cells is not yet understood. Among several possibilities, DMF may
inhibit the TNF±TNF receptor interaction. This is unlikely,
however, because the TNF-induced CD54 expression is not
blocked by DMF. Our ®nding that a 60 min preincubation with
DMF followed by washout is suf®cient to maintain endothelial cells
unresponsive to TNF raises another possibility. DMF may be taken
up into cells and lead to a persisting inhibition of signal
transduction. Interestingly, DMF is known to interfere with the
cellular glutathione metabolism (Miller et al, 1993; Nelson et al,
1999). As glutathione is known to interfere with NF-kB
translocation, this could be a possible mechanism for the observed
CD62E inhibition by DMF. As another possibility, DMF might
inhibit nuclear translocation of NF-kB p50/p65 heterodimers as
CD62E expression depends on these heterodimers. Indirect
evidence for this assumption comes from recent work by
Vandermeeren et al who found that DMF inhibited nuclear entry
of NF-kB p50 in dermal ®broblasts (Vandermeeren et al, 2001).
Importantly, Vandermeeren et al found translocation of NF-kB p65
not to be affected. Therefore, results obtained in ®broblasts cannot
easily be transposed to effects of DMF seen in endothelial cells. In
endothelium, as in many other cell types, p50/p65 is shuttled as a
complex; thus translocation of both proteins should be affected by
DMF. It is unlikely that DMF inhibits CD62E expression by
inhibiting translocation of p50 homodimers, because p50 homo-
dimers have the reverse effect ± they inhibit p50/p65 DNA binding
and transcription (Baer et al, 1998).
CaMF, EHF, and MHF exhibit an inhibitory effect on
endothelial functions only at 700 mM. At this concentration,
even interferon-g-induced HLA-DR expression on endothelial
cells is inhibited (data not shown). As HLA-DR expression is
independent from NF-kB signaling, it may be assumed that this
high concentration of FAE inhibits endothelial cell activation by
pathways other than NF-kB. With regard to DMF, speci®city for
NF-kB-dependent genes is lost at concentrations of approximately
100 mM. We thus conclude that with regard to the inhibition of
endothelial activation DMF is the therapeutic active FAE. In
endothelium, DMF appears to have a dose-dependent speci®city
for NF-kB. It thus can be assumed that the therapeutic potency of
DMF in psoriasis is due to the combined effect of DMF on
functions of endothelial cell, keratinocyte, lymphocyte, and
dendritic cell (Thio et al, 1994; Vandermeeren et al, 1997;
Ockenfels et al, 1998; Zhu and Mrowietz, 2001).
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